Video

Dr. James Lee on Overcoming Mismatched Repair in Colorectal Cancer

Author(s):

James J. Lee, MD, PhD

In Partnership With:

James J. Lee, MD, PhD, Assistant Professor of Medicine, Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, discusses mismatched repair in colorectal cancer.

James J. Lee, MD, PhD, Assistant Professor of Medicine, Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, discusses mismatched repair in colorectal cancer.

About 5% to 10% of metastatic colorectal cancers carry a very unique mutation known as mismatched repair, says Lee.

Colorectal cancer patients that have mismatched repair have a higher chance of their cancer growing and spreading.

Pembrolizumab has the potential to activate the immune system and overcome mismatched repair, says Lee.

Related Videos
Erminia Massarelli, MD, PhD, MS
Karen L. Reckamp, MD, MS
Jacob Sands, MD, oncology medical director, International Patient Center, Dana-Farber Cancer Institute; assistant professor, Harvard Medical School
Fred R. Hirsch, MD, PhD, executive director, Center for Thoracic Oncology, The Tisch Cancer Institute at Mount Sinai; Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology), Icahn School of Medicine at Mount Sinai
Lori Wirth, MD
Tanios Bekaii-Saab, MD, FACP
Moritz Fürstenau, MD
Jun Gong, MD
Thierry Facon, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Related Content
Moitreyee Chatterjee-Kishore, PhD, MBA, of Astellas
July 26th 2024

Zolbetuximab Plus Chemo Approaches EU Approval for Advanced Gastric/GEJ Cancer

Heinz-Josef Lenz, MD, FACP, about the prognostic and predictive value of HER2 gene expression for patients with KRAS wild-type metastatic colorectal cancer (mCRC). Lenz is a professor in the Department of Medicine and the Department of Preventive Medicine in the Division of Oncology at the University of Southern California (USC) Keck School of Medicine in Los Angeles. He also serves as the associate director of Clinical Research, chair of the Gastrointestinal Oncology Program, and co-director of the Colorectal Center at the USC Norris Comprehensive Cancer Center
June 3rd 2024

Lenz Discusses the Prognostic and Predictive Value of HER2 Gene Expression in KRAS Wild-Type mCRC

Hansoo Park, MD, PhD, MS, of Gwangju Institute of Science and Technology
July 25th 2024

Fecal Microbiota Transplants May Enhance Immunotherapy Efficacy in GI Cancers

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Tanios S. Bekaii-Saab, MD, FACP, of the Mayo Clinic
July 19th 2024

Complexity in GI Cancer: Questions Are Answered in Gastroesophageal Cancer, Remain in HCC

Richard Kim, MD
July 19th 2024

Exploring Unmet Needs to Optimize Neoadjuvant Therapy in Resectable CRC